#Scinai Immunotherapeutics #Israel #Jerusalem #financial results #CDMO Expansion

Scinai Immunotherapeutics' Q1 2026 Financial Overview

In a robust update released on June 10, 2026, Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) presented its financial results for the first quarter of 2026 alongside important corporate developments that resonate with its growth strategy. Scinai, recognized for blending innovative biopharmaceutical development with contract development and manufacturing organization (CDMO) services, reported significant changes that highlight its strategic intent to expand and enhance its operations.

Corporate Highlights

During this quarter, Scinai accomplished a substantial milestone by acquiring Recipharm Israel, which plays a crucial role in expanding the company's CDMO platform. This acquisition introduced a second manufacturing site located in Yavne, Israel, effectively boosting Scinai's capabilities in the biopharmaceutical arena. Furthermore, this strategic move fostered a commercial partnership with Recipharm AB, a globally recognized leader in the CDMO sector, aligning their mutual interests in delivering comprehensive development and manufacturing solutions.

The CEO of Scinai, Amir Reichman, elaborated on this pivotal phase, stating, “The first quarter of 2026 marked an important milestone in Scinai's evolution.” This sentiment underscores the company’s commitment to scaling operations, enhancing manufacturing capabilities, and expanding their commercial reach.

Moreover, Scinai has prioritized non-dilutive funding avenues to support its ongoing development programs, particularly PC111 and the NanoAb platform. The strategic focus on developing a systemic IL-17 bispecific antibody emphasizes Scinai’s commitment to delivering innovative therapeutic solutions that cater to pressing medical needs.

Financial Performance

Analyzing the financial results reveals mixed outcomes for the three months ending March 31, 2026. Scinai reported revenues of $489,000, a decrease from the prior year’s $586,000, indicating challenges while incorporating the new facility's revenues into their overall performance metrics. Notably, approximately $200,000 of this quarter’s revenue stemmed from the newly acquired Yavne facility.

The company faced an increase in the cost of revenues, rising to $1.6 million compared to $0.4 million in the previous year, primarily driven by the expansion of its CDMO operations and the implementation of a revised cost allocation strategy. This approach has resulted in some complexity in comparing costs year-on-year as certain costs were reclassified from research and development expenses.

On the R&D front, expenses witnessed a notable decrease to $0.6 million, down from $1.3 million in the same quarter last year. This reduction reflects the new allocation methodology and should not be interpreted as a diminishment of R&D efforts. Additionally, marketing, general, and administrative expenses increased slightly to $0.7 million, reflecting the operational expansion following the acquisition.

The operational loss for the company stood at $2.5 million, compared to $1.6 million in the previous year, exacerbated by heightened expenses tied to the acquisition and expanded operations.

However, Scinai recorded a net income of $3.6 million for the quarter, in contrast to a net loss of $1.6 million during the same period last year, largely attributed to a non-cash gain from a bargain purchase related to the Recipharm acquisition.

Operational Updates and Future Outlook

Scinai's strategy to broaden its CDMO platform has proven fruitful, with the recent acquisition fostering a significant operational footprint that promises to diversify revenue streams and bolster their commercial opportunities. The partnership with Recipharm places Scinai on solid footing, leveraging their integrated infrastructure across multiple manufacturing sites.

Apart from expanding their operational capabilities, Scinai remains steadfast in reinforcing their non-dilutive funding strategy, actively pursuing grants that will subsidize ongoing R&D and CDMO initiatives. Recent advancements through grant applications for both the PC111 project and their innovative NanoAb platform indicate a well-structured path towards sustained growth.

Looking ahead, Scinai's leadership emphasizes the intent to enhance CDMO revenues, secure additional funding, and continue pioneering clinical advancements. The roadmap appears promising as they focus on efficient capital allocation and maintaining strategic momentum essential for long-term shareholder value and innovation in the biopharmaceutical landscape.

As Scinai Immunotherapeutics advances its mission, the integration of operational expansions with robust funding strategies will likely serve as cornerstones of their ongoing evolution in the dynamic biopharmaceutical sector.